Metaregression showing the relationship between bleeding and antiplatelet strategy. Metaregression showing the relationship between bleeding and antiplatelet.

Slides:

Advertisements

Similar presentations

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Advertisements

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Glenn N. Levine et al. JACC 2016;68:

Achieving Long-Term Protection Post-MI

Glenn N. Levine et al. JACC 2016;68:

Nat. Rev. Cardiol. doi: /nrcardio

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Correlation between maximal workload as achieved during a physical exercise test (treadmill or bicycle; horizontal axis) and left superficial femoral artery.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Masashi Maeda et al. Heart Asia 2013;5:7-14

Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease Ehrin.

Relationship between the premature ventricular contraction (PVC) prevalence and change in left ventricular diastolic dimension (ΔLVDd) during the 4-year.

Berger JS, et al. JAMA 2009;301:

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

Comparison of CMR and echocardiography in aortic regurgitation.

Three-dimensional (3D) measurement of the outer and inner/effective mitral annular area. Three-dimensional (3D) measurement of the outer and inner/effective.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

Slope of FEV1 by age at enzyme replacement therapy (ERT) initiation FEV1 z-score slope (y-axis) by age categorised in three groups (red, ERT initiation

A large thoracoabdominal aneurysm is being resected.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

LAA device compression and LAA leakage.

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

Left panel: Correlation between left superficial femoral artery (SFA) transcutaneous partial oxygen pressure (PO2) index (horizontal axis) and the simultaneously.

Venn diagram of patients with paired pre-cardiac resynchronisation therapy (CRT) and post-CRT echocardiograms. Venn diagram of patients with paired pre-cardiac.

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Associations between presence of tachycardia at time of admission (heart rate ≥120/min) and the primary composite outcome of death or cardiovascular rehospitalisation,

(A) Quantitative plaque analysis of the RCA

Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.

Outline of the single-beat estimation of the preload recruitable stroke work relationship. Outline of the single-beat estimation of the preload recruitable.

Left: Alternations in cardiac output (black) in one typical patient, every 60 s for three cycles, are followed by oscillations in end-tidal CO2 (blue)

Bland-Altman plots for the PRSW estimates.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

(A) Absolute and B) change from baseline in 6 min walk distance over time for patients on bosentan monotherapy by Down syndrome status. (A) Absolute and.

Raw data from one individual where each 60 s cycle has been time aligned. Raw data from one individual where each 60 s cycle has been time aligned. The.

Representative images of coronary angiography and fractional flow reserve (FFR) from a patient who showed no resting ECG abnormality. Representative images.

Ejection fraction preoperatively and at follow-up in conventional (C) and no-touch (NT) groups. Ejection fraction preoperatively and at follow-up in conventional.

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

Unadjusted means by smoking status

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Phylogenetic diversity (PD) by signiﬁcant market integration factors, house modernity (A), power usage (B), and house modernity and power usage (C). Phylogenetic.

Scatter plot of relationship between MWT, GLS and EF upper panel shows that GLS was closely related to MWT with worse LV function by GLS correlating to.

Comparison of dual antiplatelet versus monotherapy in acute ischaemic stroke or transient ischaemic attack on major bleeding. A, aspirin; C, clopidogrel;

Illustrative four-chamber (left) and parasternal long axis (right) echocardiographic image of a female aged 49 years with systolic displacement of anterior.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

ROC curves showing additive value of DHE in diagnosing ongoing episode of recurrence among all patients with established history of recurrent pericarditis.

Calculating the overall accuracy in different samples using the V-plot

American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons Richard J.

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.

Patient selection process in the present study.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Forest plot of major bleeding: the measure of the effect of morphine versus nonmorphine on major bleeding in each study was plotted using OR and 95% CI.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Adjusted cumulative incidence of stroke, by sex and heart failure status. Adjusted cumulative incidence of stroke, by sex and heart failure status. The.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

The distribution of systolic blood pressure (SBP) in male (blue) and female (red) athletes with mean values (SD) presented for each sex (panel A). The.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Delayed hyperenhancement (DHE) images from patients with RP

Presentation transcript:

Metaregression showing the relationship between bleeding and antiplatelet strategy. Metaregression showing the relationship between bleeding and antiplatelet strategy. The x-axis shows DAPT duration, including aspirin monotherapy on the far left (blue panel). The y-axis shows the incidence of stroke. Individual studies are represented by circles, with study size weighting giving varying sizes. The red line denotes the gradient (β), with there being of no statistical difference between aspirin and DAPT for bleeding. DAPT, dual antiplatelet therapy. Yousif Ahmad et al. Open Heart 2018;5:e000748 ©2018 by British Cardiovascular Society